Roquefort Investments PLC (GB:ROQ) has released an update.
Roquefort Therapeutics, a biotech firm listed on the London Stock Exchange, has unveiled promising results from its STAT-6 siRNA program at the Advanced Therapy Development Congress in London. This innovative RNA interference-based therapeutic shows potential in reducing immune response, positioning Roquefort as a competitive player in the immunology and oncology markets. The company aims to partner with major pharmaceutical firms to further develop and commercialize its breakthrough therapies.
For further insights into GB:ROQ stock, check out TipRanks’ Stock Analysis page.
